2020. Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years with Uncontrolled, Severe Atopic Dermatitis: Results From Patients Who Participated in an Open-Label Phase 2a Study and then in a Subsequent Phase 3 Open-Label Extension Study. SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s104. DOI:https://doi.org/10.25251/skin.4.supp.104.